XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues [1] $ 21,761 $ 24,362 $ 74,504 $ 78,736
Cost of products sold 16,653 17,851 55,151 56,928
Gross profit 5,108 6,511 19,353 21,808
Operating expenses:        
Research and development 1,723 1,606 5,223 4,429
Selling, general and administrative 4,164 4,198 12,866 12,893
Total operating expenses 5,887 5,804 18,089 17,322
Operating (loss) income (779) 707 1,264 4,486
Other (income) expense:        
Interest and financing expense 53 92 164 372
Miscellaneous (54) (39) (88) (110)
Total other (income) expense (1) 53 76 262
(Loss) income before income tax (benefit) provision (778) 654 1,188 4,224
Income tax (benefit) provision (175) 192 290 1,010
Net (loss) income (603) 462 898 3,214
Net (loss) income attributable to non-controlling interest (18) 55 1 90
Net (loss) income attributable to Ultralife Corporation (585) 407 897 3,124
Other comprehensive (loss) income:        
Foreign currency translation adjustments (233) 677 (37) (88)
Comprehensive (loss) income attributable to Ultralife Corporation $ (818) $ 1,084 $ 860 $ 3,036
Net (loss) income per share attributable to Ultralife common stockholders – basic (in dollars per share) $ (4) $ 3 $ 6 $ 20
Net (loss) income per share attributable to Ultralife common stockholders – diluted (in dollars per share) $ (4) $ 3 $ 6 $ 19
Weighted average shares outstanding – basic (in shares) 16,065 15,908 16,020 15,889
Potential common shares (in shares) 0 181 180 214
Weighted average shares outstanding - diluted (in shares) 16,065 16,089 16,200 16,103
[1] Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects.